There are 3397 resources available
2360O - The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA71 - A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
Presenter: Xiuning Le
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Q&A and Discussion
Presenter: All Speakers
Session: Fight the enemy as soon as possible: News and views in the management of early stages colorectal cancer (CRC)
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Protein degrading cancer drugs: The promises of the new generation
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: New targets on the horizon
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: David Spiegel
Session: Protein degrading cancer drugs: The promises of the new generation
Resources:
Webcast
Invited Discussant LBA70 and LBA71
Presenter: Yi-Long Wu
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
CN1 - Integrating an electronic patient reported outcome measure (ePROM) into a nurse-led rare cancer pathway
Presenter: Jane Ireson
Session: EONS16: Opening session & Keynote lectures
Resources:
Abstract
LBA103 - ICRA: Efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1
Presenter: Sarah M.H. Einerhand
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Advancing strategies for cancer immunotherapy
Resources:
Slides
Webcast